Tvardi Therapeutics, Inc.
TVRD
$27.74
$1.104.11%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 146.42% | -43.47% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 103.70% | -59.69% | |||
| Operating Income | -103.70% | 59.69% | |||
| Income Before Tax | 143.50% | 24.62% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 143.50% | 24.62% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 143.50% | 24.62% | |||
| EBIT | -103.70% | 59.69% | |||
| EBITDA | -104.30% | 59.83% | |||
| EPS Basic | 133.77% | 24.64% | |||
| Normalized Basic EPS | 133.76% | 24.64% | |||
| EPS Diluted | 32.89% | 24.64% | |||
| Normalized Diluted EPS | 132.93% | 24.64% | |||
| Average Basic Shares Outstanding | 28.83% | 0.03% | |||
| Average Diluted Shares Outstanding | 32.09% | 0.03% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||